Whitener Capital Management’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-1,690
Closed -$415K 142
2022
Q3
$415K Sell
1,690
-400
-19% -$108K 0.2% 88
2022
Q2
$517K Hold
2,090
0.23% 83
2022
Q1
$692K Sell
2,090
-15
-0.7% -$4.62K 0.26% 81
2021
Q4
$756K Buy
2,105
+440
+26% +$149K 0.27% 76
2021
Q3
$539K Sell
1,665
-440
-21% -$149K 0.25% 78
2021
Q2
$656K Sell
2,105
-50
-2% -$15.3K 0.26% 80
2021
Q1
$682K Buy
2,155
+490
+29% +$157K 0.3% 77
2020
Q4
$539K Hold
1,665
0.25% 79
2020
Q3
$461K Sell
1,665
-10
-0.6% -$2.88K 0.22% 80
2020
Q2
$404K Hold
1,675
0.21% 82
2020
Q1
$243K Hold
1,675
0.16% 102
2019
Q4
$285K Hold
1,675
0.15% 110
2019
Q3
$297K Hold
1,675
0.16% 104
2019
Q2
$436K Hold
1,675
0.25% 83
2019
Q1
$478K Hold
1,675
0.31% 75
2018
Q4
$544K Hold
1,675
0.4% 65
2018
Q3
$753K Sell
1,675
-500
-23% -$197K 0.49% 57
2018
Q2
$889K Sell
2,175
-300
-12% -$109K 0.7% 42
2018
Q1
$720K Sell
2,475
-250
-9% -$63.4K 0.55% 52
2017
Q4
$510K Buy
+2,725
New +$509K 0.44% 65

Other funds holding ABMD

Whitener Capital Management's ABMD Position: Q4 2022 in Review

Whitener Capital Management sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 1,690 shares — an estimated $415K sold.

Whitener Capital Management first reported a position in ABMD in Q4 2017 and held it in 20 quarters. The position peaked at $889K in Q2 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Whitener Capital Management reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Whitener Capital Management sold 1,690 Abiomed Inc shares in Q4 2022, an estimated $415K.
  • Whitener Capital Management first reported a position in Abiomed Inc in Q4 2017 and held it in 20 quarters.
  • Whitener Capital Management's Abiomed Inc position peaked at $889K in Q2 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Whitener Capital Management's 13F filing for Q4 2022, filed 1 Mar 2023.